Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 1 2Phase EARLY_PHASE1 1

Status

Completed 2Unknown 1Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 4NIH 1

Study Type

Interventional 5

Sponsor

Cancer Type

Dermatologic 5Genitourinary 1

Conditions

Pancreatic Neoplasms 11Breast Neoplasms 8Prostatic Neoplasms 7Colorectal Neoplasms 7Carcinoma, Non-Small-Cell Lung 6Neoplasms 5Melanoma 5COVID-19 4Multiple Myeloma 3Lung Neoplasms 3Gastrointestinal Neoplasms 3Colonic Neoplasms 3Carcinoma, Renal Cell 3Unspecified Adult Solid Tumor, Protocol Specific 2Solid Tumor 2Recurrence 2Rectal Neoplasms 2Ovarian Neoplasms 2Neoplasms, Plasma Cell 2Neoplasm Metastasis 2Leukemia 2Glioblastoma 2Cholangiocarcinoma 2Adenocarcinoma of Lung 2Adenocarcinoma 2Urologic Diseases 1Untreated Resectable Pancreatic Adenocarcinoma 1Small Cell Lung Carcinoma 1Sarcoma, Clear Cell 1Sarcoma 1

Interventions

pembrolizumab 287Nivolumab 258Ipilimumab 236aldesleukin 134Cyclophosphamide 134Interleukin-2 104Temozolomide 75Dacarbazine 74trametinib 70Vemurafenib 69fludarabine 67dabrafenib 65fludarabine phosphate 61sargramostim 44binimetinib 44Radiosurgery 44Biopsy 43Paclitaxel 42Bevacizumab 42incomplete Freund's adjuvant 39encorafenib 37Radiotherapy 36Cisplatin 36CTLA-4 Antigen 36atezolizumab 35Carboplatin 35cobimetinib 32Magnetic Resonance Spectroscopy 32Introns 30Specimen Handling 29

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Interventional × Melanoma × Hydroxychloroquine × Clear all
NCT04464759 2026-05-11

LIMIT

Abramson Cancer Center at Penn Medicine

Phase 1/2 Recruiting
94 enrolled
Dermatologic

Melanoma

NCT01480154 2026-04-13

Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney Cancer

National Cancer Institute (NCI)

Phase 1 Active not recruiting
62 enrolled
DermatologicGenitourinary

Carcinoma, Renal Cell, Melanoma, Prostatic Neoplasms

NCT00962845 2022-09-07

Hydroxychloroquine in Patients With Stage III or Stage IV Melanoma That Can Be Removed by Surgery

Rutgers, The State University of New Jersey

Phase EARLY_PHASE1 Completed
20 enrolled
Dermatologic

Melanoma

NCT03754179 2021-04-28

COMBI-R2

Universitair Ziekenhuis Brussel

Phase 1/2 Unknown
63 enrolled
Dermatologic

Melanoma

NCT01897116 2020-05-29

A Phase I Trial of Vemurafenib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma

Abramson Cancer Center at Penn Medicine

Phase 1 Completed
8 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡